DarioHealth Corp.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving DarioHealth Corp. now
Current reporting with the operating signal separated from the noise.
DRIO|DarioHealth Corp|Price:7.250|Chg%:+0.050
The story matters when it changes DarioHealth Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.DarioHealth Corp (DRIO) Institutional Confidence
The story matters when it changes DarioHealth Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.DarioHealth Corp (DRIO) Financial Health: Profitability & Balance Sheet Analysis
Investors are testing whether DarioHealth Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.DarioHealth Corp (DRIO) Risk Assessment: Volatility, Financial Risk & Investment Risk
The story matters when it changes DarioHealth Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.DarioHealth Corp.: Dario Launches Integrated GLP-1 Program, Combining Its Digital Chronic Care Platform with Provider-Backed Clinical Care in a Single End-to-End Experience
The development tests whether DarioHealth Corp. can turn product investment into adoption, revenue and durable advantage.
Watch next: confirmation in a company filing, official release or regulator record.Form 4 DarioHealth Corp For: 28 July By Investing.com
The story matters when it changes DarioHealth Corp.’s customers, execution, competitive position or capital requirements.
Watch next: confirmation in a company filing, official release or regulator record.DarioHealth Corp. (DRIO) director buys 14,430 shares at $6.93
Investors are testing whether DarioHealth Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.DarioHealth Corp. (DRIO) Reports Q1 Loss, Beats Revenue Estimates
Investors are testing whether DarioHealth Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.DarioHealth Corp. (DRIO) Q4 2024 Earnings Call Transcript
Investors are testing whether DarioHealth Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.DarioHealth Corp. (DRIO) Q2 2024 Earnings Call Transcript
Investors are testing whether DarioHealth Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.DarioHealth Corp. (DRIO) Q2 Earnings Beat Estimates
Investors are testing whether DarioHealth Corp.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.The DarioHealth Corp. (NASDAQ:DRIO) Analysts Have Been Trimming Their Sales Forecasts
The story matters when it changes DarioHealth Corp.’s customers, execution, competitive position or capital requirements.
Watch next: official volume, pricing, inventory and segment margin.Latest DRIO filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
DarioHealth Corp., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
SEARCH Q1 COVERAGE →Second quarter
Third quarter
No verified period-specific item in the current feed.
SEARCH Q3 COVERAGE →